Significant delay and reduction of insulin use! Engler net adds to the benefits of diabetics

People with type 2 diabetes who are not effective with oral or subcutaneous injections of sugar-lowering drugs need to start insulin to control their conditionHowever, insulin therapy is more likely to pose risks such as hypoglycemia and weight gain, and for patients it means more complex treatment strategies, doctor-patient and self-management challenges, as well as higher costsReducing and delaying the demand for insulin is what both doctors and patients want to achieveanother analysis of the landmark EMPA-REG OUTCOME trial at the 80th Annual Meeting of the American Diabetes Association (2020 ADA)Compared to placebos, the SGLT2 inhibitor egress (the trade name Otangitin) significantly and consistently reduces the need for type 2 diabetes patients to initiate or strengthen existing insulin therapy, and the earlier the drug, the more significant the benefits"Patients are very concerned about the chances of eventually using insulin," said DrMuthiah Vaduganathan, lead author of thestudy and at The Brigham and Women's Hospital at Harvard Medical SchoolReducing future demand for insulin is an important part of exploring the risks and benefits of SGLT2 inhibitors with patientsThis is one of the first studies to explore the problem at finer particles, providing compelling information for doctors and patients to explore oral diabetes drug optionsEMPA-REG OUTCOME is a landmark study in the field of diabetes and cardiovascular diseaseThe study was the first to show that in patients with diabetes with combined cardiovascular disease, The SGLG2 inhibitor engress net significantly reduced the risk of major cardiovascular events, and similar drugs have only been shown in trialspublished its post-hoc analysis data, looking at the time difference between the progression of the two groups of patients and the need for new start-up insulin therapy or an increase of more than 20 percent in the total daily dose of insulinthe trial, 7020 patients with type 2 diabetes with combined cardiovascular disease from 590 clinical centers in 42 countries were treated with 10 mg or 25 mg of ngler net, or placebo, on the basis of existing anti-sugar medicationsAfter 12 weeks of treatment, patients can adjust the basic sugar reduction regimen other than the experimental drugMedian follow-up time is 3.1 yearsthe proportion of patients in the Englitnet and placebo groups who started new insulin therapy was 11.1% and 22.3%, respectively, of 3,633 patients who had not previously received insulin After adjusting other key impact variables, the demand for insulin therapy in the Engrenet group decreased significantly by 54% , newly diagnosed patients benefit more from taking engrenet, but patients with long-term illnesses still benefit significantly patients diagnosed with type 2 diabetes within 5 years of diagnosis, the need to initiate insulin therapy decreased by 69%, type 2 diabetes lasted 5-10 years, the demand was reduced by 58%, and the type 2 diabetes history was more than 10 years, the demand decreased by 44% of the 3,387 patients who had received insulin treatment at the beginning of the study, the proportion of patients with increased insulin doses in the Engler net group and the placebo group was 19.1% and 36.8%, respectively, and the risk of increased insulin dose in the Engler net group decreased by 57% as can be seen from the graph corresponding to the two indicators, the difference sefactory with the placebo group six months after the engrel net treatment has already been shown, and the difference in benefits increases over time based on these findings, the team noted that in patients with type 2 diabetes who combined cardiovascular disease, "Engre net significantly and persists in the need for patients to initiate insulin therapy and reduces the need for increased doses in patients who have used insulin." Dr Muthiah Vaduganathan, , speculates that there may be three potential mechanisms for the benefits of Ngrenet: the direct control effect of Engelnet on blood sugar; the positive effects of Engrenet on the overall health and function of patients, which can promote patient movement ; experts have also suggested more cautious thinking Dr Yehuda Handelsman, medical director of the American Institute of Metabolism, said the results were not "astonishing" and "unexpected" and that the Engler net group showed benefits, largely because patients in the placebo group had to take more insulin This is because the trial program encouraged clinicians to help patients achieve blood sugar levels, and during the period 2010-2015, patients had far fewer other oral drug options than they do today, with more than half of patients receiving routine treatment for metformin and nearly half receiving sulfonamide medication based on the trial data, Engler net also has one advantage: In addition to controlling blood sugar, it can reduce glycifying hemoglobin by about 0.5 percent, which may also help with slightly insulin sensitivity, reducing the patient's need for insulin in general, reducing insulin use is another benefit for patients As cardiovascular and renal function protection has been proven in research, SGLT2 inhibitors have been widely recommended in the diabetes guidelines More benefits from the new sugar-lowering drugs are expected, and more evidence is expected to be built up and supported in the future.